219 related articles for article (PubMed ID: 21399893)
1. Loss of Yes-associated protein (YAP) expression is associated with estrogen and progesterone receptors negativity in invasive breast carcinomas.
Tufail R; Jorda M; Zhao W; Reis I; Nawaz Z
Breast Cancer Res Treat; 2012 Feb; 131(3):743-50. PubMed ID: 21399893
[TBL] [Abstract][Full Text] [Related]
2. Expression of sex steroid receptors and their co-factors in normal and malignant breast tissue: AIB1 is a carcinoma-specific co-activator.
Hudelist G; Czerwenka K; Kubista E; Marton E; Pischinger K; Singer CF
Breast Cancer Res Treat; 2003 Mar; 78(2):193-204. PubMed ID: 12725419
[TBL] [Abstract][Full Text] [Related]
3. Estrogen receptor, progesterone receptor, and glucocorticoid receptor expression in normal breast tissue, breast in situ carcinoma, and invasive breast cancer.
Buxant F; Engohan-Aloghe C; Noël JC
Appl Immunohistochem Mol Morphol; 2010 May; 18(3):254-7. PubMed ID: 19875955
[TBL] [Abstract][Full Text] [Related]
4. Expression of DNA methylation marker of paired-like homeodomain transcription factor 2 and growth receptors in invasive ductal carcinoma of the breast.
Wan Abdul Rahman WF; Fauzi MH; Jaafar H
Asian Pac J Cancer Prev; 2014; 15(19):8441-5. PubMed ID: 25339043
[TBL] [Abstract][Full Text] [Related]
5. [Expression and clinical significance of LRP16 gene in human breast cancer].
Liao DX; Han WD; Zhao YL; Pu YD; Mu YM; Luo CH; Li XH
Ai Zheng; 2006 Jul; 25(7):866-70. PubMed ID: 16831279
[TBL] [Abstract][Full Text] [Related]
6. The prognostic potential of keratin 18 in breast cancer associated with tumor dedifferentiation, and the loss of estrogen and progesterone receptors.
Ha SA; Lee YS; Kim HK; Yoo J; Kim S; Gong GH; Lee YK; Kim JW
Cancer Biomark; 2011; 10(5):219-31. PubMed ID: 22699783
[TBL] [Abstract][Full Text] [Related]
7. Prognostic variables in invasive breast cancer: contribution of comedo versus noncomedo in situ component.
Brower ST; Ahmed S; Tartter PI; Bleiweiss I; Amberson JB
Ann Surg Oncol; 1995 Sep; 2(5):440-4. PubMed ID: 7496840
[TBL] [Abstract][Full Text] [Related]
8. Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer.
Singhal H; Greene ME; Tarulli G; Zarnke AL; Bourgo RJ; Laine M; Chang YF; Ma S; Dembo AG; Raj GV; Hickey TE; Tilley WD; Greene GL
Sci Adv; 2016 Jun; 2(6):e1501924. PubMed ID: 27386569
[TBL] [Abstract][Full Text] [Related]
9. Hypermethylation pattern of ESR and PgR genes and lacking estrogen and progesterone receptors in human breast cancer tumors: ER/PR subtypes.
Pirouzpanah S; Taleban FA; Mehdipour P; Sabour S; Atri M
Cancer Biomark; 2018 Feb; 21(3):621-638. PubMed ID: 29278880
[TBL] [Abstract][Full Text] [Related]
10. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
11. Progesterone-independent effects of human progesterone receptors (PRs) in estrogen receptor-positive breast cancer: PR isoform-specific gene regulation and tumor biology.
Jacobsen BM; Schittone SA; Richer JK; Horwitz KB
Mol Endocrinol; 2005 Mar; 19(3):574-87. PubMed ID: 15563544
[TBL] [Abstract][Full Text] [Related]
12. Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype.
Hefti MM; Hu R; Knoblauch NW; Collins LC; Haibe-Kains B; Tamimi RM; Beck AH
Breast Cancer Res; 2013; 15(4):R68. PubMed ID: 23971947
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor-negative, progesterone receptor-positive breast carcinoma: poor clinical outcome.
Keshgegian AA; Cnaan A
Arch Pathol Lab Med; 1996 Oct; 120(10):970-3. PubMed ID: 12046611
[TBL] [Abstract][Full Text] [Related]
14. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
[TBL] [Abstract][Full Text] [Related]
15. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
[TBL] [Abstract][Full Text] [Related]
16. Hormone receptors in breast cancer: more than estrogen receptors.
Lamb CA; Vanzulli SI; Lanari C
Medicina (B Aires); 2019; 79(Spec 6/1):540-545. PubMed ID: 31864223
[TBL] [Abstract][Full Text] [Related]
17. Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers.
Itoh M; Iwamoto T; Matsuoka J; Nogami T; Motoki T; Shien T; Taira N; Niikura N; Hayashi N; Ohtani S; Higaki K; Fujiwara T; Doihara H; Symmans WF; Pusztai L
Breast Cancer Res Treat; 2014 Jan; 143(2):403-9. PubMed ID: 24337596
[TBL] [Abstract][Full Text] [Related]
18. Ductal invasive mammary carcinoma--clinicopathological prognostic factors related to immunohistochemical expression of hormonal receptors and Her2/neu oncoprotein.
Recăreanu F; Simionescu C; Georgescu CV; Pirici E
Rom J Morphol Embryol; 2011; 52(3 Suppl):1059-64. PubMed ID: 22119825
[TBL] [Abstract][Full Text] [Related]
19. Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients with hormone receptor-positive tumors.
Truin W; Roumen RMH; Siesling S; van de Vijver KK; Tjan-Heijnen VCG; Voogd AC
Breast Cancer Res Treat; 2017 Jul; 164(1):133-138. PubMed ID: 28365833
[TBL] [Abstract][Full Text] [Related]
20. Clinical instability of breast cancer markers is reflected in long-term in vitro estrogen deprivation studies.
Milosevic J; Klinge J; Borg AL; Foukakis T; Bergh J; Tobin NP
BMC Cancer; 2013 Oct; 13():473. PubMed ID: 24119434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
